Alaunos Therapeutics, Inc. (NasdaqCM: TCRT)
Health Care · Biotechnology · US
$0.78
-4.88% today · -68.0% 1Y
Alaunos Therapeutics, Inc. (NasdaqCM: TCRT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.08M and employs 1 people.
Over the last twelve months the share price has lost 68.0%, trading between 0.82 and 4.59.
Tweenvest scores Alaunos Therapeutics, Inc. across four factors: quality 46/100, value 41/100. Its strongest factor is quality.
TCRT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.08M
- Revenue (TTM)
- $3.00K
- P/E
- —
- EPS
- -1.77
- Dividend yield
- —
- Beta (5Y)
- -0.87
- 52-week high
- $4.59
- 52-week low
- $0.82
- Avg volume (3M)
- —
- Shares outstanding
- 2.54M
- Employees
- 1
- Next earnings
- —
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
- ISIN
- US98973P3091
- Founded
- 2003
- Listed since
- Aug 24, 2005
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AccuStem Sciences, Inc.OTCPK: ACUT | $2.17M | $0.14 | +12.50% |
| Genprex, Inc.NasdaqCM: GNPX | $2.15M | $2.74 | +4.58% |
| HBL - Hadasit Bio-Holdings LtdTASE: HDST-M | $2.14M | ₪— | — |
| Nirman Agri Genetics LimitedNSEI: NIRMAN | $2.12M | Rs25.45 | -2.86% |
| Abpro Holdings, Inc.OTCPK: ABPO | $2.08M | $0.35 | -13.90% |
| Anatara Lifesciences LtdASX: ANR | $1.97M | AU$0.01 | -10.00% |
| Transgene Biotek LimitedBSE: 526139 | $1.89M | Rs2.40 | -7.69% |
| Cynata Therapeutics LimitedASX: CYP | $1.86M | AU$0.01 | -8.33% |
Figures last refreshed Oct 4, 2026.